Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-11-22-Speech-1-170"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-11-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Information on medicinal products (Community code relating to medicinal products) - Information on medicinal products (Community procedures for the authorisation and supervision of medicinal products) (debate)2
dcterms:Language	"hu"^^xsd:language2
lpv:document identification number	"en.20101122.17.1-170"2
lpv:hasSubsequent	lp_eu:2010-11-22-Speech-1-1712
lpv:speaker	lp:Alajos Mészáros2
lpv:spokenAs	member; EPP (2009-07-14--2014-06-30)3 unknown; Strana mad'arskej komunity- Magyar Közösség Pártja (2009-07-14--2014-06-30)3 member; JURI (2009-07-16--2012-01-18)3 member; Delegation for relations with Australia and New Zealand (2009-09-16--2014-06-30)3 substitute; Delegation for relations with the countries of Central America (2009-09-16--2011-02-07)3 substitute; ITRE (2009-07-16--2012-01-18)3
lpv:translated text	"Madam President, Mr Fjellner, too, deserves thanks for the report, for we have long needed a proposal for providing patients with more and better information on the prescription-only medicinal products prescribed to and used by them. Quality information is very important and contributes to improved healthcare conditions. When patients are adequately informed, they are more likely to follow the required treatment and will better understand the decisions relating to their treatment. What we need is not only harmonisation of European regulations. We must also ensure an improvement in public health through the provision of correct information. Pharmaceutical companies also play an important role in this. However, we must also make sure that there is no excessive drug consumption as a result of commercial promotion. There are numerous problems with the provision of information on medicines in EU Member States today. In some Member States, patients have difficulty accessing even the most basic information about prescribed medicines. This causes serious inequalities in EU healthcare. In addition to information available on the Internet, we need to provide guidance through traditional channels as well. However, our aim is not to ensure that pharmaceutical companies have the right to provide information, but to give patients the opportunity to obtain information. We need to distinguish between information and advertising. In my view, communication between patients and doctors is also important, since the primary source of information for the patient must be the physician who prescribes the medication. Other information channels should only serve to supplement that information."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph